Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study

Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study

ObjectiveThe histological conversion of lung adenocarcinoma (LUAD) into small-cell lung cancer (SCLC) is an important resistance mechanism for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-resistant LUAD. Anlotinib has been recommended as the third-line treatment for SCLC p...

Full description

Bibliographic Details
Main Authors: Jianghua Ding, Zhaohui Leng, Hong Gu, Xiang Jing, Yun Song
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Oncology
Subjects:
etoposide/platinum (EP)
anlotinib
transformation
small-cell lung cancer (SCLC)
lung adenocarcinoma (LUAD)
epidermal growth factor receptor (EGFR)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1153131/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1153131/full

Similar Items